These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 19410458)
41. Asymmetric synthesis of pochonin E and F, revision of their proposed structure, and their conversion to potent Hsp90 inhibitors. Karthikeyan G; Zambaldo C; Barluenga S; Zoete V; Karplus M; Winssinger N Chemistry; 2012 Jul; 18(29):8978-86. PubMed ID: 22696415 [TBL] [Abstract][Full Text] [Related]
42. Radester, a novel inhibitor of the Hsp90 protein folding machinery. Shen G; Blagg BS Org Lett; 2005 May; 7(11):2157-60. PubMed ID: 15901158 [TBL] [Abstract][Full Text] [Related]
43. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases. Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492 [TBL] [Abstract][Full Text] [Related]
44. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138 [TBL] [Abstract][Full Text] [Related]
45. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors. Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735 [TBL] [Abstract][Full Text] [Related]
46. Discovery of indoximod prodrugs and characterization of clinical candidate NLG802. Kumar S; Jaipuri FA; Waldo JP; Potturi H; Marcinowicz A; Adams J; Van Allen C; Zhuang H; Vahanian N; Link C; Brincks EL; Mautino MR Eur J Med Chem; 2020 Jul; 198():112373. PubMed ID: 32422549 [TBL] [Abstract][Full Text] [Related]
47. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model. Zapf CW; Bloom JD; Li Z; Dushin RG; Nittoli T; Otteng M; Nikitenko A; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Olland A; Johnson M; Levin JI Bioorg Med Chem Lett; 2011 Aug; 21(15):4602-7. PubMed ID: 21715165 [TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption. Okaniwa M; Imada T; Ohashi T; Miyazaki T; Arita T; Yabuki M; Sumita A; Tsutsumi S; Higashikawa K; Takagi T; Kawamoto T; Inui Y; Yoshida S; Ishikawa T Bioorg Med Chem; 2012 Aug; 20(15):4680-92. PubMed ID: 22763369 [TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors. Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591 [TBL] [Abstract][Full Text] [Related]
50. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781 [TBL] [Abstract][Full Text] [Related]
51. Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate Prodrug. Kung PP; Fan C; Gukasyan HJ; Huang B; Kephart S; Kraus M; Lee JH; Sutton SC; Yamazaki S; Zehnder L J Med Chem; 2021 Feb; 64(3):1725-1732. PubMed ID: 33529029 [TBL] [Abstract][Full Text] [Related]
52. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents. Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907 [TBL] [Abstract][Full Text] [Related]
53. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity. Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297 [TBL] [Abstract][Full Text] [Related]
54. Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. Chou LC; Chen CT; Lee JC; Way TD; Huang CH; Huang SM; Teng CM; Yamori T; Wu TS; Sun CM; Chien DS; Qian K; Morris-Natschke SL; Lee KH; Huang LJ; Kuo SC J Med Chem; 2010 Feb; 53(4):1616-26. PubMed ID: 20102207 [TBL] [Abstract][Full Text] [Related]
55. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90. Baruchello R; Simoni D; Grisolia G; Barbato G; Marchetti P; Rondanin R; Mangiola S; Giannini G; Brunetti T; Alloatti D; Gallo G; Ciacci A; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Guglielmi MB; Barbarino M; Foderà R; Pisano C; Cabri W J Med Chem; 2011 Dec; 54(24):8592-604. PubMed ID: 22066525 [TBL] [Abstract][Full Text] [Related]
56. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. Sun HP; Jia JM; Jiang F; Xu XL; Liu F; Guo XK; Cherfaoui B; Huang HZ; Pan Y; You QD Eur J Med Chem; 2014 May; 79():399-412. PubMed ID: 24763261 [TBL] [Abstract][Full Text] [Related]
57. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors. Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777 [TBL] [Abstract][Full Text] [Related]
58. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC). Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447 [TBL] [Abstract][Full Text] [Related]
59. Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor. Uno T; Kawai Y; Yamashita S; Oshiumi H; Yoshimura C; Mizutani T; Suzuki T; Chong KT; Shigeno K; Ohkubo M; Kodama Y; Muraoka H; Funabashi K; Takahashi K; Ohkubo S; Kitade M J Med Chem; 2019 Jan; 62(2):531-551. PubMed ID: 30525599 [TBL] [Abstract][Full Text] [Related]
60. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90). Brasca MG; Mantegani S; Amboldi N; Bindi S; Caronni D; Casale E; Ceccarelli W; Colombo N; De Ponti A; Donati D; Ermoli A; Fachin G; Felder ER; Ferguson RD; Fiorelli C; Guanci M; Isacchi A; Pesenti E; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Fogliatto G Bioorg Med Chem; 2013 Nov; 21(22):7047-63. PubMed ID: 24100158 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]